{"name":"Advenchen Laboratories Nanjing Ltd.","slug":"advenchen-laboratories-nanjing-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AL3818 Capsule","genericName":"AL3818 Capsule","slug":"al3818-capsule","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"AL8326 tablets","genericName":"AL8326 tablets","slug":"al8326-tablets","indication":"Peripheral T-cell lymphoma (PTCL)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AL58805","genericName":"AL58805","slug":"al58805","indication":"Other","status":"phase_1"},{"name":"Itraconazole capsule","genericName":"Itraconazole capsule","slug":"itraconazole-capsule","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"AL3818 Capsule","genericName":"AL3818 Capsule","slug":"al3818-capsule","phase":"phase_3","mechanism":"AL3818 is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"AL8326 tablets","genericName":"AL8326 tablets","slug":"al8326-tablets","phase":"phase_3","mechanism":"AL8326 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to alter gene expression and induce anti-tumor effects.","indications":["Peripheral T-cell lymphoma (PTCL)","Cutaneous T-cell lymphoma (CTCL)"],"catalyst":""},{"name":"AL58805","genericName":"AL58805","slug":"al58805","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Itraconazole capsule","genericName":"Itraconazole capsule","slug":"itraconazole-capsule","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}